ClariVest Asset Management LLC boosted its position in Enzo Biochem Inc. (NYSE:ENZ) by 4.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 265,503 shares of the company’s stock after buying an additional 11,300 shares during the period. ClariVest Asset Management LLC’s holdings in Enzo Biochem were worth $1,585,000 as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. Raymond James Trust N.A. purchased a new stake in shares of Enzo Biochem during the second quarter worth about $266,000. Strs Ohio purchased a new stake in shares of Enzo Biochem during the second quarter worth about $653,000. Goldman Sachs Group Inc. boosted its stake in shares of Enzo Biochem by 63.4% in the first quarter. Goldman Sachs Group Inc. now owns 173,561 shares of the company’s stock worth $790,000 after buying an additional 67,322 shares during the period. Geode Capital Management LLC boosted its stake in shares of Enzo Biochem by 3.0% in the first quarter. Geode Capital Management LLC now owns 180,845 shares of the company’s stock worth $822,000 after buying an additional 5,309 shares during the period. Finally, UBS Group AG boosted its stake in shares of Enzo Biochem by 334.7% in the first quarter. UBS Group AG now owns 206,535 shares of the company’s stock worth $940,000 after buying an additional 159,025 shares during the period. 53.29% of the stock is owned by hedge funds and other institutional investors.
Shares of Enzo Biochem Inc. (NYSE:ENZ) traded down 0.98% during trading on Thursday, hitting $5.04. 63,304 shares of the company were exchanged. Enzo Biochem Inc. has a 12 month low of $3.48 and a 12 month high of $7.00. The firm has a market capitalization of $233.17 million, a PE ratio of 13.19 and a beta of 1.50. The firm’s 50-day moving average price is $5.36 and its 200 day moving average price is $5.69.
Separately, Zacks Investment Research raised shares of Enzo Biochem from a “hold” rating to a “buy” rating and set a $6.25 price objective for the company in a research note on Thursday, June 16th.
Enzo Biochem Company Profile
Enzo Biochem, Inc (Enzo) is an integrated life science and biotechnology company, which is engaged in the research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally.
Want to see what other hedge funds are holding ENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzo Biochem Inc. (NYSE:ENZ).
Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.